About Kobo Biotech Limited
Data last updated:
Kobo Biotech Limited is a public limited company based in Hyderabad, Telangana, India. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 August 1993.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24110TG1993PLC016112. The company has 3 GST registrations on record, none of which is active. It is a listed company as per MCA records. Its shares are listed on BSE: 531541.
The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹23.83 Cr. It was formerly known as Avon Organics Ltd. It is led by directors including Sunil Mansukhlal Pitroda and Ajit Annu Kamath.
Its last annual general meeting (AGM) was held on 30 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at Hyderabad, Telangana.
Total assets are valued at ₹3.33 Cr (down 61.1% YoY).
The company has about 1 employee on its provident fund (EPFO) records.
The company is associated with 2 brands: Kobo Biotech and Avon Organics. As per MCA filings, the company has open charges of ₹169.36 Cr and satisfied charges of ₹145.09 Cr on record. Court records list 88 cases involving the company, including 21 filed by the company and 68 filed against it; 35 cases are pending. The company has 72 deals on record (72 market trades); the latest was in August 2026. The company has 26 MSME Form 1 returns on record between 2010 and 2014, listing 48 overdue payments to 7 micro and small suppliers.
The last known website on record is kobobiotech.com.
Company details
Name history
Kobo Biotech has undergone 3 name changes throughout its history. The company was previously known as Kobo Biotech Limited, Avon Organics Ltd, and Avon Lifesciences Limited. The current legal name is Kobo Biotech Limited.
| Company Name | Status |
|---|---|
| Kobo Biotech Limited | Current |
| Avon Organics Ltd | Previous |
| Avon Lifesciences Limited | Previous |
CIN history
Kobo Biotech has one previous CIN (Corporate Identification Number): L24110AP1993PLC016112. The current CIN is L24110TG1993PLC016112, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24110TG1993PLC016112 | Current |
| L24110AP1993PLC016112 | Previous |
Contact details
Kobo Biotech Limited's registered office is in Hyderabad, Telangana. Its website is kobobiotech.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressPlot No. 121A/1 Western Hills Addagutta Society Opp. Jntu Kukatpally, India, Hyderabad, Telangana, India – 500072
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Kobo Biotech Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Kobo Biotech operates two associated brands: Kobo Biotech and Avon Organics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Produces high-quality active pharmaceutical ingredients and specialty chemicals for cosmetics and pharmaceutical industries. | kobobiotech.com | |
| Limited information available | avonorganicsltd.com |
Financials of Kobo Biotech Limited
FY 2024-25 filings availableKobo Biotech Limited reported revenue of ₹- for FY 2024-25.
Financial Highlights
FY 2014-15 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2014-15 | FY 2013-14 | FY 2012-13 |
|---|---|---|---|
| Income statement | |||
| Revenue | 103 | 103 | 404 |
| Revenue growth | 0.0% | -74.4% | - |
| EBITDA | (0.91) | (0.91) | 42.87 |
| EBITDA margin | -0.9% | -0.9% | +10.6% |
| Profit before tax | (34.26) | (34.26) | 14.86 |
| Net profit | (34.80) | (34.80) | 13.98 |
| Net profit margin | -33.7% | -33.7% | +3.5% |
| EPS (₹) | (15.47) | 0.00 | 6.22 |
| Balance sheet | |||
| Total assets | 264 | 264 | 302 |
| Net worth | 53.08 | 53.08 | 87.89 |
| Total debt | 179 | 179 | 182 |
| Cash & bank | 5.64 | 5.64 | 16.48 |
| Net working capital | 161 | 161 | 193 |
| Cash flow | |||
| Cash from operations | 6.72 | 6.72 | 36.72 |
| Cash from investing | (4.71) | (4.71) | (6.99) |
| Cash from financing | (12.85) | (12.85) | (38.39) |
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | (1.23) | (0.88) | (1.50) | (10.50) | (2.78) | (0.69) | (3.90) |
| Profit before tax | (5.22) | (4.93) | (5.55) | (15.22) | (19.22) | (21.01) | (24.46) |
| Net profit | (5.22) | (4.93) | (5.55) | (15.22) | (19.22) | (21.01) | (22.28) |
| EPS (₹) | (2.20) | (2.07) | (2.33) | (6.39) | (8.07) | (8.82) | (10.27) |
| Balance sheet | |||||||
| Total assets | 3.33 | 8.56 | 13.64 | 20.06 | 155 | 165 | 172 |
| Net worth | (138) | (133) | (128) | (122) | (107) | (87.97) | (66.96) |
| Total debt | 140 | 140 | 140 | 141 | 261 | 251 | 236 |
| Cash & bank | 4.36 | 0.18 | 0.13 | 0.13 | 1.56 | 0.13 | 0.13 |
| Net working capital | (23.13) | (21.97) | (20.96) | (18.60) | 87.07 | 90.91 | 91.64 |
| Cash flow | |||||||
| Cash from operations | 4.18 | 0.20 | 0.87 | 93.76 | 2.51 | 14.48 | 20.95 |
| Cash from investing | 0.00 | 0.00 | 0.00 | 25.09 | 0.00 | 0.00 | 0.00 |
| Cash from financing | 0.00 | (0.15) | (0.87) | (120) | (1.08) | (14.47) | (20.95) |
| Particulars | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.02 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.34 | 0.25 | 0.20 | 0.20 | 0.23 | 0.79 | 0.17 | 0.21 |
| EBITDA | (0.34) | (0.25) | (0.20) | (0.20) | (0.23) | (0.79) | (0.17) | (0.21) |
| Depreciation | 1.01 | 1.01 | 1.03 | 1.02 | 1.01 | 1.00 | 1.03 | 0.89 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (1.33) | (1.26) | (1.23) | (1.22) | (1.22) | (1.79) | (1.20) | (1.10) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | FY 2014-15 | FY 2013-14 | FY 2012-13 |
|---|---|---|---|
| Revenue | 103 | 103 | 404 |
| Revenue growth | 0.0% | -74.4% | - |
| Other income | 0.25 | 0.25 | 0.37 |
| Total expenses | 104 | 104 | 361 |
| Employee cost | 9.03 | 9.03 | 12.25 |
| EBITDA | (0.91) | (0.91) | 42.87 |
| EBITDA margin | -0.9% | -0.9% | +10.6% |
| Depreciation | 9.62 | 9.62 | 9.97 |
| Interest | 23.98 | 23.98 | 18.41 |
| Profit before tax | (34.26) | (34.26) | 14.86 |
| Tax | 0.54 | 0.54 | 1.21 |
| Net profit | (34.80) | (34.80) | 13.98 |
| Net profit margin | -33.7% | -33.7% | +3.5% |
| EPS (₹) | (15.47) | 0.00 | 6.22 |
| Particulars | FY 2014-15 | FY 2013-14 | FY 2012-13 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 22.50 | 22.50 | 22.50 |
| Reserves & surplus | 30.58 | 30.58 | 65.39 |
| Shareholders' funds (net worth) | 53.08 | 53.08 | 87.89 |
| Minority interest | 0.00 | 0.00 | 0.00 |
| Secured loans | 163 | 163 | 143 |
| Unsecured loans | 16.05 | 16.05 | 38.68 |
| Total debt | 179 | 179 | 182 |
| Total liabilities | 264 | 264 | 302 |
| Assets | |||
| Gross block | 192 | 192 | 187 |
| Net block | 104 | 104 | 108 |
| Capital work in progress | 2.25 | 2.25 | 2.92 |
| Investments | 0.00 | 0.00 | 0.00 |
| Inventories | 76.01 | 76.01 | 59.31 |
| Sundry debtors | 190 | 190 | 205 |
| Cash & bank balances | 5.64 | 5.64 | 16.48 |
| Loans & advances | 18.53 | 18.53 | 20.47 |
| Total current assets | 290 | 290 | 301 |
| Total current liabilities | 129 | 129 | 108 |
| Net working capital | 161 | 161 | 193 |
| Total assets | 264 | 264 | 302 |
| Particulars | FY 2014-15 | FY 2013-14 | FY 2012-13 |
|---|---|---|---|
| Opening cash | 16.48 | 16.48 | 25.14 |
| Net cash from operating activities | 6.72 | 6.72 | 36.72 |
| Net cash from investing activities | (4.71) | (4.71) | (6.99) |
| Net cash from financing activities | (12.85) | (12.85) | (38.39) |
| Net change in cash | (10.84) | (10.84) | (8.66) |
| Closing cash | 5.64 | 5.64 | 16.48 |
| Particulars | FY 2014-15 | FY 2013-14 | FY 2012-13 |
|---|---|---|---|
| Growth | |||
| Sales growth | 0.0% | -74.4% | - |
| EBITDA growth | 0.0% | -102.1% | - |
| PBT growth | 0.0% | - | +9997.0% |
| Net income growth | 0.0% | -348.9% | - |
| Profitability & leverage | |||
| Net income margin | -33.7% | -33.7% | +3.4% |
| Return on capital employed | 0.0% | 0.0% | +12.6% |
| Return on net worth | 0.0% | 0.0% | +16.7% |
| Debt / equity | 3.38 | 2.56 | 1.83 |
| Long-term debt / equity | 0.70 | 0.55 | 0.52 |
| Interest cover | -227.73 | -227.73 | 55.96 |
| Efficiency & per share | |||
| Fixed asset turnover | 0.54 | 0.55 | 2.32 |
| Inventory turnover | 1.37 | 1.54 | 7.98 |
| Debtors turnover | 0.55 | 0.53 | 2.35 |
| EPS (₹) | (15.47) | 0.00 | 6.22 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 23.59 | 23.59 | 39.06 |
| Particulars | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.02 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.34 | 0.25 | 0.20 | 0.20 | 0.23 | 0.79 | 0.17 | 0.21 |
| EBITDA | (0.34) | (0.25) | (0.20) | (0.20) | (0.23) | (0.79) | (0.17) | (0.21) |
| Depreciation | 1.01 | 1.01 | 1.03 | 1.02 | 1.01 | 1.00 | 1.03 | 0.89 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (1.33) | (1.26) | (1.23) | (1.22) | (1.22) | (1.79) | (1.20) | (1.10) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.08 | 0.02 | 0.02 | 0.02 | 0.04 | 0.03 | 0.03 |
| Total expenses | 1.23 | 0.88 | 1.50 | 10.50 | 2.78 | 0.69 | 3.90 |
| Employee cost | 0.19 | 0.25 | 0.23 | 0.72 | 1.39 | 1.80 | 2.08 |
| EBITDA | (1.23) | (0.88) | (1.50) | (10.50) | (2.78) | (0.69) | (3.90) |
| Depreciation | 4.07 | 4.07 | 4.07 | 4.61 | 5.64 | 5.88 | 6.15 |
| Interest | 0.00 | 0.00 | 0.00 | 0.13 | 10.84 | 14.47 | 14.44 |
| Profit before tax | (5.22) | (4.93) | (5.55) | (15.22) | (19.22) | (21.01) | (24.46) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (5.22) | (4.93) | (5.55) | (15.22) | (19.22) | (21.01) | (22.28) |
| EPS (₹) | (2.20) | (2.07) | (2.33) | (6.39) | (8.07) | (8.82) | (10.27) |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 |
| Reserves & surplus | (162) | (157) | (152) | (146) | (131) | (112) | (90.79) |
| Shareholders' funds (net worth) | (138) | (133) | (128) | (122) | (107) | (87.97) | (66.96) |
| Secured loans | 108 | 108 | 108 | 109 | 229 | 219 | 205 |
| Unsecured loans | 31.71 | 31.71 | 31.71 | 31.71 | 31.71 | 31.71 | 31.71 |
| Total debt | 140 | 140 | 140 | 141 | 261 | 251 | 236 |
| Total liabilities | 3.33 | 8.56 | 13.64 | 20.06 | 155 | 165 | 172 |
| Assets | |||||||
| Gross block | 104 | 104 | 104 | 104 | 192 | 192 | 192 |
| Net block | 29.45 | 33.52 | 37.59 | 41.66 | 56.91 | 62.54 | 68.42 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 2.25 | 2.25 | 2.25 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 12.19 | 12.19 | 12.19 |
| Inventories | 18.04 | 18.04 | 18.04 | 18.04 | 53.28 | 53.28 | 53.28 |
| Sundry debtors | 12.01 | 11.97 | 11.95 | 11.80 | 92.47 | 93.29 | 90.61 |
| Cash & bank balances | 4.36 | 0.18 | 0.13 | 0.13 | 1.56 | 0.13 | 0.13 |
| Loans & advances | 7.73 | 7.69 | 7.62 | 7.56 | 11.92 | 12.65 | 12.56 |
| Total current assets | 42.14 | 37.88 | 37.74 | 37.53 | 159 | 159 | 157 |
| Total current liabilities | 65.27 | 59.85 | 58.70 | 56.13 | 72.16 | 68.44 | 64.94 |
| Net working capital | (23.13) | (21.97) | (20.96) | (18.60) | 87.07 | 90.91 | 91.64 |
| Total assets | 3.33 | 8.56 | 13.64 | 20.06 | 155 | 165 | 172 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.18 | 0.13 | 0.13 | 1.56 | 0.13 | 0.13 | 0.13 |
| Net cash from operating activities | 4.18 | 0.20 | 0.87 | 93.76 | 2.51 | 14.48 | 20.95 |
| Net cash from investing activities | 0.00 | 0.00 | 0.00 | 25.09 | 0.00 | 0.00 | 0.00 |
| Net cash from financing activities | 0.00 | (0.15) | (0.87) | (120) | (1.08) | (14.47) | (20.95) |
| Net change in cash | 4.18 | 0.05 | 0.00 | (1.43) | 1.43 | 0.00 | 0.00 |
| Closing cash | 4.36 | 0.18 | 0.13 | 0.13 | 1.56 | 0.13 | 0.13 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| EBITDA growth | -39.8% | +41.3% | +85.7% | -277.7% | -302.9% | +82.3% | - |
| PBT growth | -5.9% | +11.2% | +63.5% | +20.8% | +8.5% | +14.1% | -2.3% |
| Net income growth | -5.9% | +11.2% | +63.5% | +20.8% | +8.5% | +5.7% | - |
| Revenue CAGR (3Y) | - | - | - | - | - | - | -100.0% |
| EBITDA CAGR (3Y) | -51.1% | -31.9% | +29.5% | +39.1% | -2.7% | -44.5% | - |
| Profitability & leverage | |||||||
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | -0.86 | -128.74 | -220.24 | -143.68 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (₹) | (2.20) | (2.07) | (2.33) | (6.39) | (8.07) | (8.82) | (10.27) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | (57.98) | (55.79) | (53.72) | (51.39) | (45.00) | (36.92) | (28.11) |
To see the full year-wise statements and ratios of Kobo Biotech Limited, buy the company report.
Board of directors of Kobo Biotech Limited
Kobo Biotech has 4 current directors and 24 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sunil Mansukhlal Pitroda | Director | 31 Mar 2018 | 8 Years 6 Months | As last reported |
| Ajit Annu Kamath Also directs: Tack Commosales LLP, Arch Agro Industries Private Limited, Amra Renal Care Limited and 5 more | Director | 31 Jan 2009 | 17 Years 8 Months | As last reported |
| Urja Vijaykumar Shah | Director | 27 Dec 2018 | 7 Years 10 Months | As last reported |
| Rajendrakumar Padmanabhan Kaimal Also directs: Arch Agro Industries Private Limited, Amra Renal Care Limited, Arch Finechemicals Limited and 5 more | Director | 30 May 2013 | 13 Years 5 Months | As last reported |
Auditor
Kobo Biotech Limited is audited by A N Shah & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| A N Shah & Associates | FY 2023 | 152559W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 45.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 55.00%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 45.00% | 45.00% | 45.00% | 45.00% |
| Public | 55.00% | 55.00% | 55.00% | 55.00% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Mar 2015 | 10594602 | Others | ₹2 Cr | Open | |
| 11 Jan 2011 | 10266950 | Indian Overseas Bank | ₹20 Cr | Open | |
| 10 Jul 2009 | 10171343 | Others | ₹46.76 Cr | Open | |
| 29 Feb 2008 | 10092077 | Others | ₹69.5 Cr | Open | |
| 13 Apr 2006 | 10004469 | Punjab National Bank | ₹9 Cr | Open |
To see the full charge records of Kobo Biotech Limited, buy the company report.
Total charge records: 36 View all charges
Deals & funding
Kobo Biotech Limited has 72 deals on record (72 market trades); the latest was in August 2026.
Deals on record (5 of 72)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2026 | Market trade | ₹10.8 Lakh | Buyer: an individual Seller: Multiplier Share and Stock Advisors Private Limited |
| Jul 2026 | Market trade | ₹12.8 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited |
| Oct 2017 | Market trade | ₹1.17 Cr | Buyer: an individual Seller: Blue Peacock Securities Private Limited , an individual |
| Oct 2015 | Market trade | ₹2.15 Cr | Buyer: Palladium Finserve Private Limited Seller: Palladium Finserve Private Limited |
| Aug 2015 | Market trade | ₹3.89 Cr | Buyer: Vivid Finance and Holdings Private Limited , Shaktiman Steel Casting Pvt Ltd. Seller: Graceunited Developers Private Limited , Shaktiman Steel Casting Pvt Ltd. |
To see the full deal history of Kobo Biotech Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Kobo Biotech Limited has 88 court cases on record: 21 filed by Kobo Biotech, 68 filed against it. 35 cases are pending and 53 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 56 | 53 | 28 |
| High courts | 28 | 12 | 4 |
| NCLAT | 2 | 2 | 2 |
| Supreme Court | 1 | 0 | 0 |
| NCLT | 1 | 1 | 1 |
Cases on record (5 of 88)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court for State of Telangana | Writ petition | Filed by the company against JM Financial Asset Reconstruction Company Limited and 1 other | Pending |
| NCLT, Hyderabad | Insolvency matter | Filed against the company by JM Financial Asset Reconstruction Company Limited | Pending |
| High Court, TELANGANA | Writ petition | Filed against the company by JM Financial Asset Reconstruction Company Limited | Pending |
| Bombay High Court | Commercial suit | Filed against the company by Canbank Factors Limited | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Civil suit | Filed against the company by Canbank Factors Ltd Th. Mr. Uday Shiva Gajinkar | Pending |
To see the full case history of Kobo Biotech Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Kobo Biotech Limited has 26 MSME Form 1 returns on record between 2010 and 2014, listing 48 overdue payments to 7 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 7)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Silicon Products Private Associates | |||
| Aswathi Industries Limited | |||
| Orbit Pumps & Systems Private Limited | |||
| Altop Industries Ltd |
To see the full MSME payment records of Kobo Biotech Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Kobo Biotech Limited has a workforce of 1 employees on its EPFO records as of Apr 09, 2024, across 1 active EPFO establishment.
GST
Kobo Biotech has 3 GST registrations on record, and all of them have been cancelled or are inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Kobo Biotech Limited, buy the company report.
Recent activity
Kobo Biotech Limited has 48 board changes on record since 1993: 26 appointments and 22 cessations. The latest: Ravindra Baikuthanath Chaturvedi ceased to be Irp/Rp/Liquidator on 13 Feb 2025.
122 earlier events are in the company report.
Frequently asked questions
Kobo Biotech is undergoing "Corporate Insolvency Resolution Process" (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency resolution professional. The company may not be able to independently enter into new commitments during this period. This is a high-risk status - verify the resolution status before any engagement.
Kobo Biotech is a company under insolvency, formerly operating as a public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 August 1993 and is registered under CIN L24110TG1993PLC016112. Listed on BSE: 531541. Caution is advised - the company may not have the legal capacity to fulfil new agreements.
Kobo Biotech has 4 current directors:
- Sunil Mansukhlal Pitroda - Director
- Ajit Annu Kamath - Director
- Urja Vijaykumar Shah - Director
- Rajendrakumar Padmanabhan Kaimal - Director
The latest financial statements of Kobo Biotech on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 30 September 2023. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Kobo Biotech is L24110TG1993PLC016112. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Kobo Biotech is a listed company as per MCA records. Its shares are listed on BSE (code: 531541).
Kobo Biotech has open charges of ₹169.36 Cr and satisfied charges of ₹145.09 Cr as per latest MCA filings.
Kobo Biotech has 88 court cases on record: 21 filed by the company and 68 filed against it. 35 are pending. Most are in the district courts.
Kobo Biotech was incorporated on 03 August 1993. It is registered with the Registrar of Companies, Hyderabad.
Kobo Biotech has 72 deals on record (72 market trades); the latest was in August 2026.
Ravindra Baikuthanath Chaturvedi ceased to be Irp/Rp/Liquidator on 13 Feb 2025. Ravindra Baikuthanath Chaturvedi was appointed as Irp/Rp/Liquidator on 29 Aug 2024. Abhishek Deepak Buddhadev ceased to be Director on 30 May 2024. Kobo Biotech has 48 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
